130 related articles for article (PubMed ID: 2650061)
1. Immunosuppression with an anti-IL-2 receptor monoclonal antibody in a baboon renal allograft model.
Hayes JM; Spencer W; Valenzuela R; Caulfield M; Novick AC
Transplant Proc; 1989 Feb; 21(1 Pt 1):1006-9. PubMed ID: 2650061
[No Abstract] [Full Text] [Related]
2. Monoclonal anti-IL-2 receptor antibody in primate renal transplantation.
Shapiro ME; Kirkman RL; Reed MH; Puskas JD; Mazoujian G; Letvin NL; Carpenter CB; Milford EL; Waldmann TA; Strom TB
Transplant Proc; 1987 Feb; 19(1 Pt 1):594-8. PubMed ID: 3103282
[No Abstract] [Full Text] [Related]
3. Anti-TAC MOAB prolongs renal allografts in cynomolgus monkeys.
Reed MH; Shapiro ME; Strom TB; Carpenter CB; Letvin NL; Reimann K; Weinberg DS; Waldmann TA; Kirkman RL
Transplant Proc; 1989 Feb; 21(1 Pt 1):1028-30. PubMed ID: 2650064
[No Abstract] [Full Text] [Related]
4. Phenotypic and functional analysis of kidney infiltrating T cells escaping monoclonal antibody treatment in primate renal transplantation.
Nocera A; Cosimi AB; Colvin RB; Gesner ML; Fuller TC
Transplant Proc; 1988 Apr; 20(2):205-6. PubMed ID: 3129830
[No Abstract] [Full Text] [Related]
5. Early experience with anti-Tac in clinical renal transplantation.
Kirkman RL; Shapiro ME; Carpenter CB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
Transplant Proc; 1989 Feb; 21(1 Pt 2):1766-8. PubMed ID: 2652578
[No Abstract] [Full Text] [Related]
6. Anti-interleukin-2 receptor monoclonal antibody therapy in rats: comparison of the effector mechanisms mediated by variant murine isotypes.
Stünkel KG; Grützmann R; Diamantstein T; Kupiec-Weglinski JW; Schlumberger HD
Transplant Proc; 1989 Feb; 21(1 Pt 1):1003-5. PubMed ID: 2784878
[No Abstract] [Full Text] [Related]
7. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts.
Waldmann TA; Goldman CK
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):45-53. PubMed ID: 2683757
[TBL] [Abstract][Full Text] [Related]
8. Prolongation of fetal pancreas allograft survival in mice treated with anti-IL-2 receptor monoclonal antibody (PC61) conjugated with idarubicin.
Koulmanda M; Pietersz G; McKenzie IF; Mandel TE
Transplant Proc; 1990 Oct; 22(5):2113-4. PubMed ID: 2219312
[No Abstract] [Full Text] [Related]
9. The use of monoclonal antibodies against activated human T cells following renal allografting in the baboon.
Friend PJ; Tighe H; Lim S; Collier DS; Decurtins M; Gilliland LK; Thiru S; Calne R; Waldmann H
Transplant Proc; 1987 Oct; 19(5):4317-8. PubMed ID: 3314035
[No Abstract] [Full Text] [Related]
10. Anti-interleukin-2 receptor (IL-2R) antibody against rejection of organ grafts.
Kupiec-Weglinski JW; Padberg W; Uhteg LC; Towpik E; Lord RH; Ma L; Diamantstein T; Strom TB; Tilney NL
Transplant Proc; 1987 Feb; 19(1 Pt 1):591-3. PubMed ID: 2978926
[No Abstract] [Full Text] [Related]
11. Selective sparing of T suppressor cells by anti interleukin-2 receptor monoclonal antibodies (IL-2R mAbs) in vitro correlates with their therapeutic effects in vivo.
Tanaka K; Turka LA; Ueda H; Diamantstein T; Milford EL; Carpenter CB; Tilney NL; Kupiec-Weglinski JW
Transplant Proc; 1989 Feb; 21(1 Pt 1):475-6. PubMed ID: 2523145
[No Abstract] [Full Text] [Related]
12. Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (MAb) therapy: target cell depletion or inhibition of function?
Tellides G; Dallman MJ; Morris PJ
Transplant Proc; 1989 Feb; 21(1 Pt 1):997-8. PubMed ID: 2650306
[No Abstract] [Full Text] [Related]
13. Treatment of presensitization with IL-2 receptor antibody plus alloantigen.
Tyler JD; Wierwille SL; Goldman MH
Transplant Proc; 1989 Feb; 21(1 Pt 1):1010-2. PubMed ID: 2650062
[No Abstract] [Full Text] [Related]
14. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A.
Diamantstein T; Mouzaki A; Osawa H; Volk HD; Hahn HJ; Kirkman RL; Strom TB; Tilney NL; Kupiec-Weglinski JW
Dev Biol Stand; 1988; 69():177-84. PubMed ID: 3066671
[No Abstract] [Full Text] [Related]
15. Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation.
Carpenter CB; Kirkman RL; Shapiro ME; Milford EL; Tiney NL; Waldmann TA; Zimmerman CE; Ramos EL; Strom TB
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):54-7. PubMed ID: 2683758
[TBL] [Abstract][Full Text] [Related]
16. Local immunosuppressive therapy with monoclonal anti-T-cell antibody on renal allograft survival in the rat. II. Phenotypic and functional assessment of spleen cells.
Yoshimura N; Lee CJ; Shiho O; Kita M; Imanishi J; Oka T
Transplant Proc; 1995 Feb; 27(1):390-1. PubMed ID: 7879033
[No Abstract] [Full Text] [Related]
17. Immunosuppression in small bowel transplantation--treatment with a monoclonal IL-2 receptor antibody (NDS 61).
Schweizer E; Papachrysanthou A; Faendrich F; Deltz E; Schroeder P
Transplant Proc; 1994 Dec; 26(6):3142-3. PubMed ID: 7998095
[No Abstract] [Full Text] [Related]
18. Immunosuppression by anti-interleukin-2 receptor antibody but not anti-L3T4 requires terminal complement components.
Kelley VE; Strom TB
Transplant Proc; 1987 Feb; 19(1 Pt 1):617. PubMed ID: 3274827
[No Abstract] [Full Text] [Related]
19. The role of a primate model of renal transplantation in the development of new monoclonal antibodies.
Shapiro ME; Reed MH; Strom TB; Carpenter CB; Milford EL; Kirkman RL
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):58-60. PubMed ID: 2816938
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood monitoring during and after rejection-prophylaxis with a monoclonal anti-interleukin-2-receptor antibody in kidney and heart transplant recipients.
van Gelder T; Knoop CJ; Hesse CJ; Vaessen LM; Balk AH; Yzermans JN; Weimar W
Transplant Proc; 1995 Feb; 27(1):856-8. PubMed ID: 7879206
[No Abstract] [Full Text] [Related]
[Next] [New Search]
